構造ベース創薬におけるタンパク質結晶化戦略

Efficient structure-based design requires robust protocols for generating protein-ligand complex structures to support iterative chemical optimization. However, developing reliable crystallization conditions suitable for drug discovery remains challenging, especially for novel targets and when working with diverse ligand classes.

The review focuses on establishing robust crystallization workflows and providing solutions when standard methods prove inadequate for obtaining protein-ligand crystal structures. In addition to reviewing the literature for generic technical advances, the authors provide a comprehensive overview of project- and protein-specific approaches. To further substantiate their claims, the authors analyzed metadata from their proprietary structure collection, representing 20 years of crystallography supporting structure-based drug design. The authors provide two detailed examples showcasing rescue strategies in action.

Crystal structures will remain fundamental to structure-based drug design moving forward. Successful crystallization demands adaptable, multi-faceted strategies that systematically explore diverse protein variants and crystallization conditions. Future progress depends on integrating AI tools for construct design with project insights and robust experimental workflows. Success ultimately hinges on synergy between innovative problem-solving approaches and deep expertise in navigating this rapidly evolving landscape.